Skip to main content
Clinical Trials/ITMCTR1900002806
ITMCTR1900002806
Not yet recruiting
Phase 1

Clinical study for the prevention and treatment of rheumatoid arthritis by Hua-Yu Qiang-Shen Tong-Bi Decoction

Guangdong Provincial Hospital of Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Rheumatoid Arthritis
Sponsor
Guangdong Provincial Hospital of Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational study
Sex
All

Investigators

Sponsor
Guangdong Provincial Hospital of Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. diagnostic criteria:
  • (1\) meet the ACR/EULAR 2010 revised criteria for RA;
  • (2\) diagnostic criteria of TCM syndrome: the TCM syndrome diagnosis criteria refers to the Diagnostic Basis and Syndrome Classification of the Guidelines for the Combination of Diagnosis and Treatment of Rheumatoid Arthritis issued by the China Association of Chinese Medicine in 2019\. The syndrome differentiation of TCM is cold\-damp syndrome and/or wind\-damp syndrome.
  • 2\. disease activity assessed by DAS28\-CRP score. Patients with low disease activity (3\.2 \>DAS28\-CRP\>2\.6\) will be recruited;
  • 3\. between 18 to 65 years of age;
  • 4\. have not been treated with DMARDs or have been treated with DMARD but not take DMARDs for at least 1 week prior to screening;
  • 5\. agree to participate in the study and sign an informed consent form.

Exclusion Criteria

  • 1\. have a history of another autoimmune rheumatic disease such as Sjogrens syndrome or Systemic lupus erythematosus; with acute or chronic infection, including hepatitis B or hepatitis C infection; evidence of active, latent, or inadequately treated Mycobacterium tuberculosis infection; have a history of cancer;
  • 2\. patients with severe cardiovascular, brain, lung, liver, kidney, or hematopoietic diseases;
  • 3\. pregnant women or breastfeeding mothers or those with known psychiatric disorders;
  • 4\. a hemoglobin level of less than 90g/L, a white cell count of less than 3\.0x10^9/L, or a platelet count of less than 100x10^9/L;
  • 5\. an estimated glomerular filtration rate of 40 ml per minute or less;
  • 6\. the aspartate aminotransferase or alanine aminotransferase level higher than 1\.5 times the upper limit of the normal range;
  • 7\. patients with an active gastroduodenal ulcer or gastritis caused by the long\-term use of NSAIDs;
  • 8\. patients that are found to be hypersensitive to the trial medication;
  • 9\. patients that have participated in other clinical trials within 4 weeks of screening.

Outcomes

Primary Outcomes

Not specified

Similar Trials